Insulin pump treatment in type 1 diabetes mellitus – for whom and why?

Czech version

Authors: Dana Prídavková; Veronika Sváková; Udovít Šutarík; Marián Mokáň
Authors‘ workplace: I. interná klinika Jesseniovej LF UK a UNM, Martin
Published in: Forum Diab 2019; 8(2): 139-146
Category: Review Article

Overview

Insulin pump treatment, also known as continuous subcutaneous insulin infusion (CSII), is an important part of the diabetes mellitus (DM) treatment portfolio. This is an effective and flexible method of administering insulin that, when properly indicated and managed, generally leads to improved glycemic compensation and variability, reduction of GHbA₁ (glycosylated hemoglobin), reduced frequency of severe hypoglycemia, correction of „dawn“ or „dark“ phenomena, reduction of „unawareness hypoglycemia“ syndrome, but also leads to the reduction of the total insulin dose compared to multiple daily injections (MDI), also contributes to improving the quality of life of diabetic patients.

Keywords:

continuous subcutaneous insulin infusion – multiple daily injections

Sources

Subramanian S, Baidal D, Skyler JS et al. The Management of Type 1 Diabetes [Updated 2017]. In: Feingold KR, Anawalt B, Boyce A et al. Endotext, South Darthmouth (MA): MDText.com, Inc., 2000. Dostupné z WWW: <https://www.ncbi.nlm.nih.gov/pubmed/25905160>.
Kesavadev J, Kumar Das A, Unnikrishnan R et al. Use of Insulin Pumps in India: Suggeseted Guidelines Based on Experience and Cultural Difference. Diabetes Technol Ther 2010; 12(10): 823–831. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2010.0027>.
Pickup JC, Keen H, Parsons JA et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med 1978; 1(6107): 204–207.
Pozzilli P, Battelino T, Danne T et al. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev 2016; 32(1): 21–39. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.2653>.
Doničová V, Brož J, Sorin I. Health Care Provision for People with Diabetes and Postgraduate Training of Diabetes Specialists in Eastern European Countries. J Diabetes Sci Technol 2011; 5(5): 1124–1136. Dostupné z DOI: <http://dx.doi.org/10.1177/193229681100500513>.
Renard E. Insulin pump use in Europe. Diabetes Technol Ther 2010; 12(Suppl1): S29-S32. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2009.0189>.
Martinka E, Mokáň M, Uličiansky V et al. Konsenzuálny terapeutický algoritmus pre liečbu pomocou inzulínovej pumpy a kontinuálne meranie glykémie (v súlade s aktuálnym znením indikačných obmedzení). Forum Diab 2016; 5(2): 111–120.
Hannaire H, Lassmann-Vague V, Jeandidier N et al. Treatment of diabetes mellitus using an external insulin pump: the state of the art. Diabetes and metabolism 2008; 34(4 Pt 2): 401–423. Dostupné z DOI: <http://dx.doi.org/10.1016/S1262–3636(08)73972–7>.
Reznik Y (ed). Handbook of Diabetes Technology. Springer International 2019. Hardcover ISBN 978–3-319–98118–5. eBook ISBN 978–3-319–98119–2. Dostupné z DOI: <http://dx.doi.org/10.1007/978–3-319–98119–2>.
User Manual for Dana Diabecare R. Dostupné z WWW: <http://www.sooil.com/bbs/board.php?bo_table=data_eng&wr_id=11&sca=Manuals>.
Thethi TK, Rao A, Kawji H et al. Consequences of delayed pump infusion line change in patients with Type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications 2010; 24(2): 73–78. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2009.03.002>
Nathan DM, Genuth S, Lachin J et al. [Diabetes Control and Complications Trial Research Group]. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977–986. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199309303291401>.
Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25): 2643–2653. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa052187>.
Misso ML, Egberts KJ, Page M et al. Continuous subcutaneous insulin infusion (CSII) versus multiple daily injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010; (1):CD005103. <http://dx.doi.org/10.1002/14651858.CD005103.pub2>.
Hirsch IB, Bode BW, Garg S et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injections of insulin aspart/insulin glargin in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005; 28(3):533–538.
Retnakaran R, Hochman J, DeVries JH et al. Continuous subcutaneous insulin infusion versus mlutiple daily injections: The impact of baseline A1c. Diabetes Care 2004; 27(11): 2590–2596.
Karges B, Schwandt A, Heidtmann B et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA 2017; 318(14): 1358–1366. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2017.13994>.
Haynes A, Hermann JM, Miller KM et al. Severe hypoglycemia rates are not associated with HbA1c: a cross-sectional analysis of 3 contemporary pediatric diabetes registry databases. Pediatr Diabetes 2017; 18(7): 643–650. Dostupné z DOI: <http://dx.doi.org/10.1111/pedi.12477>.
Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: metaanalysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25(7): 765–774. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1464–5491.2008.02486.x>.
Birkebaek NH, Drivvoll AK, Aakeson K et al. Incidence of severe hypoglycemia in children with type 1 diabetes in the Nordic countries in the period 2008–2012: association with hemoglobin A1c and treatment modality. BMJ Open Diabetes Res Care 2017; 5(1): e000377. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjdrc-2016–000377>.
[American Diabetes Association] Standards of Medical Care in Diabetes -2019. Diabetes Care 2019; 42(Suppl 1): S1-S2. Dostupné z DOI: < https://doi.org/10.2337/dc19-Sint01>.
[Medical Advisory Secretariat]. Continuous subcutaneous insulin infusion pumps for type 1 and type 2 adult diabetic populations: an evidence‐based analysis. Ontario Health Technology Assessment 2009; 9(20): 1–58.
Jeitler K, Horvath K, Berghold A et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta‐analysis. Diabetologia 2008;51(6): 941–951. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–008–0974–3>.
Jacobsen IB, Henriksen JE, Hother‐Nielsen O et al. Evidence‐based insulin treatment in type 1 diabetes mellitus. Diabetes Res Clin Pract 2009; 86(1): 1–10. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2009.05.020>.
Chantelau E, Spraul M, Mühlhauser I et a. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 1989; 32(7): 421–426.
[Diabetes Control and Complications Trial Research Group]. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995;18(11): 1415–1427.
Egger M, Davey Smith G, Stettler C et al. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med 1997; 14(11): 919–928. Dostupné z DOI: <http://dx.doi.org/10.1002/(SICI)1096–9136(199711)14:11<919::AID-DIA456>3.0.CO;2-A>.
Maahs DM, Hermann JM, Holman N et al. [National Paediatric Diabetes Audit and the Royal College of Paediatrics and Child Health, the DPV Initiative, and the T1D Exchange Clinic Network]. Rates of diabetic ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the U.S., Austria, and Germany. Diabetes Care 2015; 38(10): 1876–1882. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15–0780>.
Maiorino MI, Bellastella G, Casciano O et al. The Effects of Subcutaneous Insulin Infusion Versus Multiple Insulin Injections on Glucose Variability in Young Adults with Type 1 Diabetes: The 2-Year Follow-Up of the Observational METRO Study. Diabetes Technol Ther 2018; 20(2): 117–126. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2017.0334>.
Leporo G, Corsi A, Dodesini AR et al. Continuous Subcutaneous Insulin Infusion Is Better Than Multiple Daily Insulin Injections in Reducing Glucose Variability Only in Type 1 Diabetes With Good Metabolic Control. Diabetes Care 2010; 33(6): e81-e81. Dostupné z DOI: <https://doi.org/10.2337/dc10–0355>.
Ceriello A, Esposito K, Piconi L et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008; 57(5): 1349–1354. Dostupné z DOI: <http://dx.doi.org/10.2337/db08–0063>.
Steineck I, Cederholm J, Eliasson B et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study. BMJ 2015; 350:h3234. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.h3234>.